An additional 1,400 patients who had received a DePuy ARS metal-on-metal hip implant are now eligible to participate in the U. S. Settlement Program to receive compensation for their revision surgeries.
DePuy Orthopaedics, a subsidiary of Johnson & Johnson, announced that it has agreed to extend the existing U.S. Settlement Program to include eligible patients in the U.S. who had surgery to remove and replace their defective implants after Aug. 31, 2013 and on or before Jan. 31, 2015. The previous settlement, announced in November 2013, did not compensate eligible patients who had revision surgery after Aug. 30, 2013.
The agreement was made Feb. 20, 2015, between DePuy and the court-appointed committee of lawyers representing plaintiffs who were suing DePuy over the defective implants.
A DePuy spokesman said that extending the benefits to more patients was “again providing fair compensation to U.S. ASR patients without the delay and uncertainty of protracted litigation.”
In 2010, DePuy recalled its ASR metal-on-metal hip implants after a higher than expected number of failures in just five years or less. Not only were the devices found to loosen, fracture or dislocate, they were also corroding inside patients’ bodies, leaching metal ions into the bloodstream causing a type of blood poisoning known as metallosis. Treatment includes revision surgery to remove and replace the defective device – a surgical procedure that is more dangerous and requires longer recovery than the original surgery to implant the device.
Each of the 1,400 new patients in the settlement program who had an ASR hip implant removed since 2013 will receive about $300,000 each in compensation. The group joins about 8,000 other patients who were a part of the original settlement agreement. The payout is expected to near $4 billion.
Source: Ortho Spine News